Back
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Back
Stock News
Themes
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Transcenta Rises 2.4% After Dosing First Patient in Antibody Trial
Edgen Stock
·
Jan 14 2026, 17:22
Share to
Share to
Copy link
QYUNS-B
NaN%
source:
[1] Transcenta Holding (02509.HK) completes first subject dosing in Phase I clinical trial for QX030N/CLD-423
Recommend
Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder Returns
Nov 28 2025, 10:17
US-China AI Rivalry Enters New Phase Focused on Compute Power and Cybersecurity
Nov 28 2025, 10:17
Enterprise Products Partners Nears Financial Inflection Point, Poised for Enhanced Shareholder Returns
Nov 28 2025, 10:17